News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
The 2023 President’s Innovation Prize (PIP) and President’s Engagement Prize (PEP) winners have each made significant strides over the course of the past year.
Mike Mitchell, PhD, was interviewed recently by the Philadelphia Inquirer about his cutting-edge research in lipid nanoparticles (LNPs), which are crucial for delivering mRNA into the body's cells.
The University of Pennsylvania School of Veterinary Medicine (Penn Vet) has launched an mRNA Research Initiative to advance the development of veterinary mRNA-based vaccines and therapies.
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.
Pennsylvania legislators are working on new ways to retain young residents who too often leave the region for opportunities after receiving their education within the state.
Recently proposed guidance could expand "march-in rights" under the Bayh-Dole Act, significantly impacting the development of products from federally funded research.
PCI and Penn Medicine partnered with Citizens JMP for the inaugural ‘Novel Therapeutics Forum’ at Penn.
ToxiSense is developing a plant-based alternative to test for bacterial toxins in vaccines and medical devices, which could eliminate the current need for bloodletting of horseshoe crabs.
Linnaeus Therapeutics, Inc. announced the issuance of EP patent 3823617 by the European Patent Office (EPO) covering the pharmaceutical composition of matter for their lead compound, LNS8801.
Exyn Technologies, a PCI Ventures portfolio company focused on multi-platform robotic autonomy, is receiving global recognition for its groundbreaking drone software.